SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13D - General statement of acquisition of beneficial ownership:
SEC Accession No. 0000947871-20-000594
Filing Date
2020-06-29
Accepted
2020-06-29 18:27:38
Documents
3
Group Members
ORBIMED CAPITAL GP V LLC

Document Format Files

Seq Description Document Type Size
1 SCHEDULE 13D ss176854_sc13d.htm SC 13D 81530
2 JOINT FILING AGREEMENT ss176854_ex9901.htm EX-99.1 5475
3 LOCK-UP AGREEMENT ss176854_ex9902.htm EX-99.2 47598
  Complete submission text file 0000947871-20-000594.txt   136225
Mailing Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022
Business Address 601 LEXINGTON AVENUE 54TH FLOOR NEW YORK NY 10022 (212) 739-6400
ORBIMED ADVISORS LLC (Filed by) CIK: 0001055951 (see all company filings)

IRS No.: 133976876 | State of Incorp.: DE
Type: SC 13D

Mailing Address 245 FIRST STREET, 3RD FLOOR CAMBRIDGE MA 02142
Business Address 245 FIRST STREET, 3RD FLOOR CAMBRIDGE MA 02142 617-500-8099
Compass Therapeutics, Inc. (Subject) CIK: 0001738021 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13D | Act: 34 | File No.: 005-90878 | Film No.: 20998448
SIC: 2836 Biological Products, (No Diagnostic Substances)